Cargando…

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor

Objective: The aim of this study was to evaluate the pharmacokinetic profile of lesogaberan in healthy subjects after single oral and intravenous administration of (14)C-labeled lesogaberan and non-(14)C-labeled lesogaberan. Study Design: This was an open-label, single-center, randomized, two-way cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niazi, Mohammad, Skrtic, Stanko, Ruth, Magnus, Holmberg, Ann A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585951/ https://www.ncbi.nlm.nih.gov/pubmed/21410297 http://dx.doi.org/10.2165/11590310-000000000-00000

Ejemplares similares

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis
por: Bhattacharya, Dipankar, et al.
Publicado: (2021)

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study
por: Miner, Philip B, et al.
Publicado: (2014)

Antitussive effects of the peripherally restricted GABA(B) receptor agonist lesogaberan in guinea pigs: comparison to baclofen and other GABA(B) receptor-selective agonists
por: Canning, Brendan J, et al.
Publicado: (2012)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication
por: Tian, Jide, et al.
Publicado: (2017)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study
por: Johannsson, Gudmundur, et al.
Publicado: (2016)

3,3,5,5-Tetramethyl-r-2,c-6-diphenylpiperidin-4-one
por: Govindaraju, C., et al.
Publicado: (2012)

Synthesis of C‐14 labeled GABA(A) α2/α3 selective partial agonists and the investigation of late‐occurring and long‐circulating metabolites of GABA(A) receptor modulator AZD7325
por: Artelsmair, Markus, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals
por: Lim, Wen Hui, et al.
Publicado: (2022)

Effect of a high‐fat and high‐calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects
por: Wu, Qingqing, et al.
Publicado: (2023)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

3355 The CTSA Institutional website: A higher purpose - Researcher use of institutional Clinical and Translational Science Award (CTSA) website content to assess or promote NCATS CTSA Program Goals.
por: Tafuto, Barbara Ann
Publicado: (2019)

Post-reflux swallow-induced peristaltic wave (PSPW): physiology, triggering factors and role in reflux clearance in healthy subjects
por: Zhang, Mengyu, et al.
Publicado: (2020)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Propofol pharmacokinetics in young healthy Indian subjects
por: Puri, Avinash, et al.
Publicado: (2012)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
por: Markowitz, John S., et al.
Publicado: (2022)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough
por: Badri, Huda, et al.
Publicado: (2022)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

Transcriptomic and phenotype analysis revealed the role of rpoS in stress resistance and virulence of a novel ST3355 ESBL-producing hypervirulent Klebsiella pneumoniae isolate
por: Zhou, Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ccmbqodvfgtaqkhmd327ovcbtn